Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.59 |
| ▸ | SQLE | Q14534 | 6/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | FNTA | P49354 | 1/20 | 0.50 |
| ▸ | FNTB | P49356 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8621731 | 1.00 | KMT2A (0.67) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL8623413 | 1.00 | KMT2A (0.67) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL8623417 | 1.00 | KMT2A (0.67) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL9128197 | 1.00 | KMT2A (0.67) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL8618551 | 0.94 | KMT2A (0.64) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL9129115 | 0.94 | KMT2A (0.64) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL8618554 | 0.94 | KMT2A (0.64) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL9129108 | 0.94 | KMT2A (0.64) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL8624351 | 0.92 | KMT2A (0.61) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL8620673 | 0.92 | KMT2A (0.61) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| WO-1996019484-A1 | NOVEL CARBOXAMIDE-DERIVED PHOSPHONATES, METHOD FOR MAKING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID PHOSPHONATES | PIERRE FABRE MEDICAMENT (FR) | 1996-06-27 | — | — | WO | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| US-5428028-A | Method for lowering cholesterol employing a phosphonomethylphosphinate squalene synthetase inhibitor | E. R. SQUIBB & SONS, INC. (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0601573-A1 | Alpha-phosphonocarboxylate squalene synthetase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-06-15 | — | — | EP | disclosed |
| US-5312814-A | Antilipemic agents or anticholesterol agents | BRISTOL-MYERS SQUIBB CO. (US) | 1994-05-17 | — | — | US | disclosed |
| EP-0589473-A1 | Hydroxyphosphinyl phosphonate squalene synthetase inhibitors and their use in pharmaceutical compositions | E.R. SQUIBB & SONS, INC. (US) | 1994-03-30 | — | — | EP | disclosed |
| US-5254544-A | Anticholesterol | E. R. SQUIBB & SONS, INC. (US) | 1993-10-19 | — | — | US | disclosed |
| EP-0513761-A2 | Bisphosphonate squalene synthetase inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| EP-0514124-A2 | Use of phosphonomethylphosphinate squalene synthetase inhibitors for the manufacture of a medicament for the lowering cholesterol | E.R. SQUIBB & SONS, INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| US-5157027-A | Anticholesterol agents | E. R. SQUIBB & SONS, INC. (US) | 1992-10-20 | — | — | US | disclosed |